Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration.
<h4>Purpose</h4>To analyze the risk factors associated with emerging intraocular inflammation (IOI) after intravitreal brolucizumab injection (IVBr) to treat age-related macular degeneration (AMD).<h4>Methods</h4>This study included 93 eyes of 90 patients. The incidence of em...
Main Authors: | Ryo Mukai, Hidetaka Matsumoto, Hideo Akiyama |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0259879 |
Similar Items
-
Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
by: Hidetaka Matsumoto, et al.
Published: (2023-02-01) -
Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment
by: Natsuki Ueji, et al.
Published: (2023-10-01) -
Visual outcomes of intraocular inflammation after brolucizumab injection in Japanese patients with neovascular age-related macular degeneration.
by: Kazushi Hirono, et al.
Published: (2024-01-01) -
Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Ashwin Gupta, et al.
Published: (2022-01-01) -
Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
by: Emilia Maggio, et al.
Published: (2022-09-01)